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Question 1
Answer: a. Rosacea has an estimated incidence of 1.7 per 1,000 person-years in general practice in the UK.
Mrs RP has read about ivermectin 1% cream and asks her doctor whether she might benefit from using it. In two double-blind randomised vehicle-controlled trials what was the change in inflammatory lesion count with ivermectin compared with placebo? 
Question 2
Answer: d. Ivermectin is very toxic to invertebrates and represents an environmental hazard. Although, the Summary of Product Characteristics recommends taking care to prevent environmental contamination, in particular of water, no specific practical guidance is given.
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Answer: c. Ivermectin produced a statistically significant difference in the primary outcome measure of the percentage change in inflammatory lesion counts from baseline (mean lesion count of 33) to week 16 (reduction of 83% with ivermectin vs. 74% with metronidazole, p<0.001).
In 
Question 4
Answer: e. The most commonly reported unwanted effects in clinical trials (occurring in up to 1% of patients) were skin burning sensation, skin irritation, and itchy and dry skin.
